Alnylam Pharmaceuticals (ALNY) Inventory Average (2018 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Inventory Average came in at $90.6 million in Q2 2026, up 31.96% YoY from $68.6 million in Q2 2025, and up 8.63% on a QoQ basis from $83.4 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Inventory Average (2018 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 9 years of Inventory Average data on file, last reported at $90.6 million in Q2 2026.
- Quarterly Inventory Average rose 31.96% year-over-year to $90.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $90.6 million (up 31.96% YoY) and the FY2025 annual result came in at $80.6 million, down 3.83% from the prior year.
- Inventory Average grew to $90.6 million in Q2 2026, from $83.4 million in the prior quarter.
- In the past five years, Inventory Average ranged from a high of $130.4 million in Q1 2023 to a low of $68.6 million in Q2 2025.
- A 5-year average of $90.7 million and a median of $86.4 million in 2022 frame the typical range for Inventory Average.
- Annual changes were most pronounced in 2023 — Inventory Average surged 58.2% — and 2024, when it dropped 29.79%.
- Tracing ALNY's Inventory Average over 5 years: stood at $122.2 million in 2022, then decreased by 24.35% to $92.5 million in 2023, then declined by 16.45% to $77.2 million in 2024, then advanced by 2.33% to $79.1 million in 2025, then rose by 14.57% to $90.6 million in 2026.
- The last three Inventory Average figures came in at $90.6 million (Q2 2026), $83.4 million (Q1 2026), and $79.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.09 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 707.10 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 355,998.06 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 90.57 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 137.65 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.57 Mn |
| Mar 31, 2026 | 83.37 Mn |
| Dec 31, 2025 | 79.05 Mn |
| Sep 30, 2025 | 73.54 Mn |
| Jun 30, 2025 | 68.63 Mn |
| Mar 31, 2025 | 72.05 Mn |
| Dec 31, 2024 | 77.25 Mn |
| Sep 30, 2024 | 79.98 Mn |
| Jun 30, 2024 | 88.98 Mn |
| Mar 31, 2024 | 91.57 Mn |
| Dec 31, 2023 | 92.46 Mn |
| Sep 30, 2023 | 98.11 Mn |
| Jun 30, 2023 | 116.17 Mn |
| Mar 31, 2023 | 130.42 Mn |
| Dec 31, 2022 | 122.23 Mn |
| Sep 30, 2022 | 102.23 Mn |
| Jun 30, 2022 | 83.75 Mn |
| Mar 31, 2022 | 82.44 Mn |
| Dec 31, 2021 | 92.13 Mn |
| Sep 30, 2021 | 91.13 Mn |